Characteristics | All patients (n = 24) | Group | ||
---|---|---|---|---|
A (n = 11) | B (n = 13) | P-value | ||
Disease severity | Â | Â | Â | 0.776 |
 Mild (%) | 0/24 (0) | 0/11 (0) | 0/13 (0) |  |
 Moderate (%) | 23/24 (95.83) | 11/11 (100) | 12/13 (92.31) |  |
 Severe (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) |  |
 Critical (%) | 0/24 (0) | 0/11 (0) | 0/13 (0) |  |
Complications | ||||
 ARDS (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
Treatment | ||||
 Antibiotics | 17/24 (70.83) | 9/11 (81.82) | 8/13 (61.54) | 0.386 |
 Antifungal drugs | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
 Antiviral drugs (%) | 24/24 (100) | 11/11 (100) | 13/13 (100) | – |
 Glucocorticoids (%) | 5/24 (20.83) | 2/11 (18.18) | 3/13 (23.08) | 1 |
 Albumin (%) | 11/24 (45.83) | 2/11 (18.18) | 9/13 (69.23) | 0.019 |
 Immunoglobulin (%) | 6/24 (25.00) | 2/11 (18.18) | 4/13 (30.77) | 0.649 |
 Thymosin (%) | 15/24 (62.50) | 7/11 (63.64) | 8/13 (61.54) | 1 |
Oxygen therapy (%) | 11/24 (45.83) | 4/11 (36.36) | 7/13 (53.85) | 0.444 |
 Common (%) | 10/11 (90.91) | 4/4 (100) | 6/7 (85.71) | 1 |
 HFNC (%) | 1/11 (9.09) | 0/4 (0) | 1/7 (14.29) |  |
TCM (%) | 24/24 (100) | 11/11 (100) | 13/13 (100) | – |